InsidersTradesSigma
Follow the 力生制药 stock price and the full directors' dealings record of the company, a listed issuer based in China. Shares are quoted on the CN market, under the authority of SSE / SZSE (CSRC). The latest transaction was reported on 4 August 2026 (Purchase). Among the most active insiders: 郭晓燕. The full history is openly available.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
力生制药 is a company focused on the research, development, and manufacturing of pharmaceutical products in China. It specializes in treatments for various diseases and medical conditions.